United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

rosemont pharmaceuticals ltd - dipyridamole - oral suspension - 10mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - atomoxetine hydrochloride - oral solution - 4mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - olanzapine, quantity: 20 mg - tablet, orally disintegrating - excipient ingredients: mannitol; microcrystalline cellulose; guar gum; crospovidone; magnesium stearate; colloidal anhydrous silica; aspartame; sodium lauryl sulfate - olanzapine is indicated for the treatment of schizophrenia and related psychoses. olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - olanzapine, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: sodium lauryl sulfate; mannitol; microcrystalline cellulose; guar gum; crospovidone; magnesium stearate; colloidal anhydrous silica; aspartame - olanzapine is indicated for the treatment of schizophrenia and related psychoses. olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - olanzapine, quantity: 10 mg - tablet, orally disintegrating - excipient ingredients: aspartame; magnesium stearate; mannitol; microcrystalline cellulose; colloidal anhydrous silica; sodium lauryl sulfate; crospovidone; guar gum - olanzapine is indicated for the treatment of schizophrenia and related psychoses. ,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - olanzapine, quantity: 5 mg - tablet, orally disintegrating - excipient ingredients: crospovidone; sodium lauryl sulfate; colloidal anhydrous silica; microcrystalline cellulose; aspartame; magnesium stearate; mannitol; guar gum - olanzapine is indicated for the treatment of schizophrenia and related psychoses. ,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - amoxicillin trihydrate; potassium clavulanate - oral suspension - 80mg/1ml ; 11.4mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - amoxicillin trihydrate; potassium clavulanate - oral suspension - 50mg/1ml ; 12.5mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - potassium clavulanate; amoxicillin trihydrate - oral suspension - 6.25mg/1ml ; 25mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - lansoprazole, quantity: 15 mg - tablet, orally disintegrating - 15 mg - excipient ingredients: iron oxide yellow; polysorbate 80; purified talc; microcrystalline cellulose; titanium dioxide; lactose monohydrate; aspartame; hyprolose; macrogol 8000; iron oxide red; magnesium carbonate hydrate; magnesium stearate; crospovidone; mannitol; glyceryl monostearate; hypromellose; triethyl citrate; citric acid; polyacrylate dispersion (30 per cent); purified water; methacrylic acid copolymer; sodium lauryl sulfate; flavour - adults 1. healing and long-term management of reflux oesophagitis. 2. healing and long-term management for patients with duodenal ulcer. 3. healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 4. lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists. 5. eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials). 6. relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. paediatric patients 6 to 17 years of age. 1. treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. 2. healing of erosive oesophagitis.